生物活性 | |||
---|---|---|---|
描述 | Guanabenz Acetate is an alpha2 adrenergic receptor agonist shown to interact with a regulatory subunit of the protein phosphatase, Pp1/Gadd34, and selectively disrupt the dephosphorylation of the alpha subunit of eukaryotic initiation factor 2.Guanabenz treatment accelerated ALS-like disease progression in a strain of mutant SOD1 transgenic ALS(Amyotrophic Lateral Sclerosis) mice[3]. Guanabenz Acetate is capable of markedly increasing the cellular internalization and target mRNA silencing of hydrophobically modified siRNAs (hsiRNAs), yielding a ∼100-fold decrease in hsiRNA IC50 (from 132 nM to 2.4 nM)[4]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02423083 | Multiple Sclerosis, Relapsing-... 展开 >>Remitting Multiple Sclerosis 收起 << | Phase 1 | Terminated | - | United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 << |
NCT02443103 | Bone Cancer M... 展开 >>etastasis 收起 << | Not Applicable | Terminated(Slow accrual) | - | United States, Indiana ... 展开 >> Indiana University Health Hospital Indianapolis, Indiana, United States, 46202 Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 Sidney & Lois Eskenazi Hospital Indianapolis, Indiana, United States, 46202 Spring Mill Medical Center Indianapolis, Indiana, United States, 46290 收起 << |
NCT02443103 | - | Terminated(Slow accrual) | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.43mL 0.69mL 0.34mL |
17.17mL 3.43mL 1.72mL |
34.35mL 6.87mL 3.43mL |
参考文献 |
---|